| DC67123 |
Genevant CL1 monohydrochloride |
Genevant CL1 monohydrochloride is an ionizable lipid (lipid 10, pKa=6.3), and it can be used for mRNA lipid nanoparticle (LNP) vaccine delivery. |
|
| DC67124 |
Cho-Arg TFA |
Cho-Arg TFA is a steroid-based cationic lipid with an L-Arginine headgroup. Cho-Arg TFA shows a remarkably high optimized plasmid DNA transfection efficacy. |
|
| DC67126 |
80-O18
Featured
|
80-O18 is a lipidoid that promotes high total cellular uptake with promising delivery capabilities. |
|
| DC67132 |
C16 PEG750 Ceramide |
C16 PEG750 Ceramide (C16 PEG Ceramide (MW 750)) is a PEG lipid for the preparation of liposomes and can be used in drug delivery studies. |
|
| A743 |
Loncastuximab
Featured
|
Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL). |
|
| A744 |
Denintuzumab
Featured
|
Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab can be used as the antibody moiety (ADC antibody) of antibody-drug conjugates to synthesize ADC, Denintuzumab Mafodotin (SGN-CD19A). Denintuzumab Mafodotin can be used in the research of acute lymphoblastic leukemia. |
|
| A745 |
Obexelimab
Featured
|
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus. |
|
| A746 |
Coltuximab
Featured
|
|
|
| A747 |
Duke U. patent anti-CD19
Featured
|
|
|
| A748 |
Immunomedics hA19
Featured
|
|
|
| A749 |
Siplizumab
Featured
|
Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells. |
|
| A750 |
TRU-015
Featured
|
|
|
| A751 |
Ripertamab
Featured
|
Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL). |
|
| A752 |
Ublituximab
Featured
|
Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects. |
|
| A753 |
Zuberitamab
Featured
|
Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma. |
|
| A754 |
Veltuzumab
Featured
|
Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL). |
|
| A755 |
Obinutuzumab
Featured
|
Obinutuzumab (GA101) a novel glycoengineered Type II CD20 humanized IgG1 monoclonal antibody in development for non-Hodgkin lymphoma. |
|
| A756 |
Ocaratuzumab
Featured
|
Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC). |
|
| A757 |
Divozilimab
Featured
|
Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab can be used for multiple sclerosis research. |
|
| DC67136 |
SARM1-IN-2
Featured
|
SARM1-IN-2 (Example 82) is a SARM1 inhibitor with an IC50 value of <1 μM. SARM1-IN-2 inhibits axonal regrowth, leading to only 6% regrowth after 72 h of exposure. SARM1-IN-2 can be used for the research of axonal degeneration. |
|
| DC67137 |
SARM1-IN-3
Featured
|
SARM1-IN-3 (Example 30) is a SARM1 inhibitor. SARM1-IN-3 can be used in the study of chemotherapy induced peripheral neuropathy (CIPN). |
|
| DC67138 |
SARM1 Human Pre-designed siRNA Set A
Featured
|
SARM1 Human Pre-designed siRNA Set A contains three designed siRNAs for SARM1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. |
|
| DC67139 |
TFM-4AS-1
Featured
|
TFM-4AS-1 is a selective androgen receptor modulator (SARM), and a potent androgen receptor (AR) ligand with an IC50 of 38 nM. TFM-4AS-1 is a gene-selective agonist. |
|
| DC67140 |
LG-121071
Featured
|
LG-121071 is an orally active and selective androgen receptor modulator with a Ki of 17 nM. |
|
| DC67141 |
S-40503
Featured
|
S-40503 is an orally active and selective androgen receptor modulator. S-40503 significantly increases the bone mineral density (BMD) and biomechanical strength of femoral cortical bone. |
|
| DC67142 |
5-Chloroisoquinoline
Featured
|
5-Chloroisoquinoline (compound 42) is an inhibitor of SARM1 (Sterile alpha and toll/interleukin receptor (TIR) motif containing protein 1), an enzyme involved in axon degeneration that catalyzes multiple activities through a ternary complex mechanism. 5-Chloroisoquinoline can be used in the study of neurodegenerative diseases or axon degeneration. |
|
| DC67143 |
(+)-JNJ-37654032
Featured
|
(+)-JNJ-37654032 is an orally active and selective androgen receptor modulator. (+)-JNJ-37654032 can be used in the study of muscle-wasting diseases. |
|
| DC67144 |
Phenazopyridine
Featured
|
Phenazopyridine is a competitive SARM1 inhibitor, with IC50 145 μM. Phenazopyridine is a TRPM8 antagonist. Phenazopyridine has a local anesthetic/analgesic effect. Phenazopyridine is used to relieve painful symptoms of conditions such as cystitis and urethritis. Phenazopyridine can promote neuronal differentiation and can also be used in the study of traumatic brain injury, peripheral neuropathy and neurodegenerative diseases. |
|
| DC67145 |
2-Amino-5-methylhexane
Featured
|
|
|
| DC67146 |
YK11
Featured
|
|
|
